Abstracts Archive - Page 946 of 2425 - ACR Meeting Abstracts

Abstract Number: 2816 • 2019 ACR/ARP Annual Meeting
An Expanded Granzyme K+ CD8 T Cell Population Induces Inflammatory Responses in Rheumatoid Arthritis Synovium
Anna Helena Jonsson¹, Fan Zhang ², Gerald Watts ², Kevin Wei ¹, Deepak Rao ², Soumya Raychaudhuri ² and Michael Brenner ³, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospital:, Boston
Background/Purpose: CD8 T cells represent nearly half of T cells in inflamed synovium from patients with rheumatoid arthritis (RA). Research to date has focused on…
Abstract Number: 2817 • 2019 ACR/ARP Annual Meeting
Lysosomal Placement of the Energy Sensors AMPK and mTORC1 Controls Tissue Inflammation in Rheumatoid Arthritis
Zhenke Wen ¹, Ke Jin ¹, Yinyin Li ¹, Bowen Wu ¹, Jorg Goronzy ¹ and Cornelia Weyand¹, ¹Stanford University, Stanford, CA
Background/Purpose: CD4 T cells from patients with rheumatoid arthritis (RA) are metabolically reprogrammed, diverting glucose away from glycolysis towards the production of biosynthetic precursors. Several…
Abstract Number: 2818 • 2019 ACR/ARP Annual Meeting
Differences in the Phenotypic Landscape and Antigen Specificity of CD4+ T Cells Are Present in CCP+ Subjects Before the Onset of Rheumatoid Arthritis
Virginia Muir ¹, Cliff Rims ¹, Kevin Deane ², Jeffrey Carlin ³, Sylvia Posso ¹, Sunil Nagpal ⁴, Navin Rao ⁴, Frédéric Baribaud ⁵, George Vratsanos ⁶, William Robinson ⁷, Gary Firestein ⁸, V. Michael Holers ⁹, Peter Linsley ¹, Eddie James¹ and Jane Buckner ¹, ¹Benaroya Research Institute, Seattle, WA, ²University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ³Virginia Mason Medical Center, Seattle, WA, ⁴Janssen R&D, Spring House, PA, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶JNJ, Raritan, NJ, ⁷Stanford University, Palo Alto, CA, ⁸University of California, San Diego, San Diego, ⁹University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver
Background/Purpose: The “Targeting Immune Responses for Prevention of RA” (TIP-RA) collaboration studies individuals at high risk for developing rheumatoid arthritis (RA) because of serum anti-citrullinated…
Abstract Number: 2819 • 2019 ACR/ARP Annual Meeting
The Transcription Factor MAF Controls the Ability of T Peripheral Helper (Tph) Cells to Help B Cells
Alexandra Bocharnikov¹, Vanessa Wacleche ¹, Ye Cao ¹ and Deepak Rao ², ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Pathologic T cell-B cell interactions are hallmark features of many autoimmune diseases. PD-1hi CXCR5- T peripheral helper (Tph) cells are B cell-helper T cells…
Abstract Number: 2820 • 2019 ACR/ARP Annual Meeting
Calcium/ Calmodulin – Dependent Protein Kinase IV Associates with Phosphofructokinase to Promote Glycolysis and Limit IL-2 Production
Milena Vukelic¹, Nobuya Yoshida ², Masataka Umeda ³, Seo Yeon Orite ³, Rhea Bhargava ³, Michihito Kono ⁴, Irina Gavanescu-Stockton ³, Ryo Hisada ³ and George Tsokos ², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA, ⁴Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is disease characterized by an imbalance between pro-inflammatory (such as Th1 and Th17) and regulatory cells (Tregs). Th1 and Th17…
Abstract Number: 2821 • 2019 ACR/ARP Annual Meeting
Clonal Expansion of a Specific Subset of Cytotoxic CD4+T Cells and Tissue Apoptosis in Patients with IgG4-related Disease
Cory Perugino¹, Naoki Kaneko ², Jesper Kers ³, Takashi Maehara ², Hamid Mattoo ⁴, Hang Liu ⁵, Vinay Mahajan ⁵, Musie Ghebremichael ⁵, Hugues Allard-Chamard ⁵, Yesim Tuncay ⁵, Emanuel Della Torre ⁶, Zachary Wallace ¹, Lloyd Liang ¹, Sydney Montesi ⁷, John Stone ⁸ and Shiv Pillai ⁹, ¹Massachusetts General Hospital, Boston, ²Kyushu University, Fukuoka, Japan, ³University of Amsterdam, Amsterdam, Netherlands, ⁴Sanofi, Cambridge, ⁵Ragon Institute of MGH, MTI and Harvard, Cambridge, ⁶Hospital San Raffaele, milan, Italy, ⁷Massachusetts General Hospital, Boston, MA, ⁸Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁹Ragon Institude of MGH, MIT and Harvard, Charlestown, MA
Background/Purpose: In IgG4-related disease (IgG4-RD), both activated B cells and CD4+ cytotoxic T lymphocytes (CD4+CTLs) expand clonally, accumulate in tissues, likely recognize distinct epitopes on…
Abstract Number: 2824 • 2019 ACR/ARP Annual Meeting
Antibiotic Use and the Development of Rheumatoid Arthritis (RA) and Risk of RA Flares: Case-Control and Self-Controlled Case Series Studies in Two National Electronic Patient Databases (SIDIAP and CPRD)
Navraj Nagra¹, Danielle Robinson ², Antonella Delmestri ¹, Stephanie Dakin ¹, Sarah Snelling ¹, Andrew Carr ¹ and Daniel Prieto-Alhambra ¹, ¹University of Oxford, Oxford, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: The microbiome and specific bacterial triggers have been hypothesised to be involved in the pathogenesis of Rheumatoid Arthritis (RA) and RA flares. Antibiotic usage…
Abstract Number: 2825 • 2019 ACR/ARP Annual Meeting
Provider Variability in Glucocorticoid Prescribing for Patients with Rheumatoid Arthritis and Impact on Chronic Glucocorticoid Use
Michael George¹, Joshua Baker ², Lang Chen ³, Qufei Wu ², Fenglong Xie ⁴, Huifeng Yun ³ and Jeffrey Curtis ³, ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham
Background/Purpose: Glucocorticoids are recommended as short-term bridging therapy in patients with rheumatoid arthritis (RA), but as many as 30-40% of patients remain on glucocorticoids chronically.…
Abstract Number: 2826 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infections in Tofacitinib versus Other Biologic Drug Initiators in Patients with Rheumatoid Arthritis: A Multi-database Cohort Study
Ajinkya Pawar ¹, Rishi Desai ¹, Nileesa Gautam ¹ and Seoyoung C. Kim², ¹Brigham and Women's hospital, Boston, ²Brigham and Women’s Hospital and Harvard Medical School, Boston
Background/Purpose: It is well-known that biologic or targeted synthetic DMARDs increase the risk of serious infections (SIs), but few studies have directly compared the risk…
Abstract Number: 2827 • 2019 ACR/ARP Annual Meeting
Weight Fluctuation and Risk of Cardiovascular Events in Patients with Rheumatoid Arthritis
Joshua Baker¹, George Reed ² and Joel Kremer ³, ¹University of Pennsylvania, Philadelphia, PA, ²Corrona Research Foundation, Waltham, MA, ³Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Fluctuations in weight (weight cycling) occur in rheumatoid arthritis (RA) in association with severe disease features and comorbidity. In the general population, weight fluctuation…
Abstract Number: 2828 • 2019 ACR/ARP Annual Meeting
Implementing the BP Connect Systems-Based Blood Pressure Follow-Up Protocol with Community Rheumatology Clinic Teams
Edmond Ramly ¹, Douglas White ², Amanda Perez ¹ and Christie Bartels¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Gundersen Health System, Onalaska
Background/Purpose: Despite recognition that rheumatoid arthritis (RA) accelerates cardiovascular disease (CVD) and hypertension impacts 50% of RA patients, up to 50% lack blood pressure (BP)…
Abstract Number: 2829 • 2019 ACR/ARP Annual Meeting
Improving SLE Care by Enhancing Medication Adherence Using a Tailored Clinic Intervention: HCQ-Crosswalk
Shivani Garg¹, Betty Chewning ², Karen Hansen ³, Beth Martin ² and Christie Bartels ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²UW - School of Pharmacy, Madison, Madison, ³UW Madison, Madison
Background/Purpose: Up to 83% of patients with SLE are nonadherent to hydroxychloroquine (HCQ) which results in a 36% higher risk of renal failure, and 8-fold…
Abstract Number: 2830 • 2019 ACR/ARP Annual Meeting
Treatment Delays Associated with Prior Authorization for Infusible Medications: A Cohort Study
Zachary Wallace¹, Tyler Harkness ¹, Xiaoqing Fu ¹, John Stone ², Hyon K. Choi ³ and Rochelle Walensky ¹, ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Boston, MA
Background/Purpose: Prior authorizations (PA) are commonly required by health payers as cost-containment strategies for expensive medications, including infused biologics. In rheumatology, these medications are frequently…
Abstract Number: 2831 • 2019 ACR/ARP Annual Meeting
Cracks in Your Referral Process? Find Your Sustainable Solution Here
Sheetal Vora¹, Amanda Moyer ², Lynn Kalhagen ², Anna Sherrod ², Thomas Griffin ², Kristen Corcoran ², Sarah Mabus ² and Talia Buitrago ², ¹Atrium Health, Charolotte, ²Atrium Health, Charlotte
Background/Purpose: Early diagnosis for rheumatic conditions is crucial for children to achieve the best functional outcomes. Access to care is difficult due to the volume…
Abstract Number: 2832 • 2019 ACR/ARP Annual Meeting
Using a Learning Collaborative to Develop an RA Disease Activity Communication Tool to Promote Shared Decision-Making in Treat to Target
Lucy Liu¹, Sonam Choden ², Jennifer Barton ³, Puneet Bajaj ⁴, Christie Bartels ⁵, Maria Danila ⁶, Elizabeth Wahl ⁷, Kimberly Reiter ⁸, Joann Zell ⁹, Christina Downey, MD ¹⁰, Elena Weinstein ¹¹, Gabriela Schmajuk ² and Jinoos Yazdany ¹², ¹UCSF, Oakland, CA, ²UCSF, SFVAMC Division of Rheumatology, San Francisco, CA, ³VA Portland Health Care System & Oregon Health & Science University, Portland, OR, ⁴UT Southwestern, Dallas, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷VA Puget Sound, Seattle, WA, ⁸Albuquerque VA Medical Center, University of NM School of Medicine, Albuquerque, NM, ⁹Denver Health, Denver, CO, ¹⁰Loma Linda University Medical Center, Loma LInda, CA, ¹¹University of Colorado Department of Rheumatology, Denver, CO, ¹²UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: A treat to target (T2T) approach in managing RA can improve patient outcomes. A key component to T2T is establishing personalized treatment targets through…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].